Researchers report dietary 1,5-anhydro-D-fructose attenuates sarcopenia phenotypes in animal models

A study published in The Journal of Nutritional Biochemistry reports that dietary 1,5-anhydro-D-fructose reduces sarcopenia-related phenotypes and hepatic fibrosis in C. elegans and aged mouse models, suggesting potential as a nutritional intervention for age-related muscle decline.

Researchers evaluated the effects of dietary 1,5-anhydro-D-fructose (1,5-AF) in cross-species aging models of Caenorhabditis elegans and aged mice.

In C. elegans, dietary administration of 1,5-AF enhanced late-life locomotor activity and upregulated transcripts encoding myofibrillar proteins.

In aged mouse models, 1,5-AF administration improved forelimb grip strength and reduced the presence of rimmed vacuole-containing muscle fibers.

The treatment promoted a shift toward an oxidative muscle fiber phenotype and increased the expression of mitochondrial-related proteins in the skeletal muscle of aged mice.

Beyond skeletal muscle, 1,5-AF administration attenuated hepatic lipid accumulation and fibrosis, and showed a trend toward reduced macrophage accumulation.

Sarcopenia represents a significant age-related health challenge with limited pharmacological treatments, highlighting the need for effective nutritional interventions.

The multi-tissue benefits observed—affecting both muscle function and hepatic pathology—suggest that 1,5-AF may influence systemic metabolic pathways associated with aging.

The cross-species validation in both invertebrate (C. elegans) and mammalian (mouse) models provides a stronger biological rationale for further testing in human clinical trials compared to single-species studies.

These findings may stimulate interest in 1,5-AF as a potential functional food ingredient or dietary supplement targeting muscle health and metabolic aging.

The dual effect on muscle sarcopenia and hepatic fibrosis positions 1,5-AF within the broader context of metabolic and tissue aging, though clinical development will be required to validate these preclinical findings in humans.

Companies developing therapies for muscle wasting, metabolic diseases, or liver fibrosis may monitor these developments to assess how nutritional interventions like 1,5-AF could complement or compete with therapeutic pipelines.

Future clinical trials designed to evaluate the safety, tolerability, and efficacy of dietary 1,5-AF supplementation in elderly populations experiencing sarcopenia or muscle weakness.

Mechanistic studies to identify the precise molecular pathways through which 1,5-AF regulates mitochondrial function, muscle fiber phenotypes, and hepatic lipid metabolism.